Shu Wen Li

Impax Laboratories (Taiwan), Inc. engages in the research, development and manufacturing of oral controlled-release dosage forms of generic drugs. It also involves in the formulation and clinical development of alternate dosage forms of drugs for diseases in the central nervous system. Its products include branded pharmaceutical product such as IPX066 and generic pharmaceutical products such as Acarbose, Dantrolene Sodium, and Fenofibrate tablets. The company was founded on May 4, 2007 and is headquartered in Miaoli, Taiwan.

Impax Laboratories (Taiwan), Inc. engages in the research, development and manufacturing of oral controlled-release dosage forms of generic drugs. It also involves in the formulation and clinical development of alternate dosage forms of drugs for diseases in the central nervous system. Its products include branded pharmaceutical product such as IPX066 and generic pharmaceutical products such as Acarbose, Dantrolene Sodium, and Fenofibrate tablets. The company was founded on May 4, 2007 and is headquartered in Miaoli, Taiwan.

Impax Laboratories (Taiwan), Inc. engages in the research, development and manufacturing of oral controlled-release dosage forms of generic drugs. It also involves in the formulation and clinical development of alternate dosage forms of drugs for diseases in the central nervous system. Its products include branded pharmaceutical product such as IPX066 and generic pharmaceutical products such as Acarbose, Dantrolene Sodium, and Fenofibrate tablets. The company was founded on May 4, 2007 and is headquartered in Miaoli, Taiwan.